Σάββατο 31 Μαρτίου 2018

Glucocorticoids as an adjunct to oncologic treatment in solid malignancies – not an innocent bystander

Publication date: Available online 31 March 2018
Source:Critical Reviews in Oncology/Hematology
Author(s): Corinne Maurice-Dror, Ruth Perets, Gil Bar-Sela
Glucocorticoids are steroidal hormones which exert their action via genomic and non-genomic mechanisms. In the clinical setting, glucocorticoids are utilized for their anti-inflammatory, anti-allergenic and immunomodulatory effects and for their well-established, pro-apoptotic effects on hematological malignancies. In the treatment of solid tumors, glucocorticoids serve primarily for alleviation of tumor- and treatment-related symptoms and in most cases are not considered to have a direct effect on tumor growth and spread. However, significant pre-clinical data suggest that glucocorticoids have diverse effects on tumor progression, both pro- and anti- tumorigenic. In contrast, the clinical data regarding the pro- and anti-tumorigenic effects of glucocorticoids on solid tumors is scarce, and summarized in this review. The following review presents the suggested glucocorticoids mechanism of action and the effects of glucocorticoids on tumor cells, on the tumor microenvironment and on tumor response to cytotoxic therapy, in the pre-clinical and clinical settings.



https://ift.tt/2J8Lf9L

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου